Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Dianthus Therapeutics, Inc. reported revenue of $2M, down 67.3% year over year. Operating margin was -8739.3% and net margin -7973.3%, on a free-cash-flow margin of -6349.4% with capital expenditure at 10.5% of revenue. Every figure is computed directly from DNTH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2M | -8739.3% | -7973.3% |
| FY2024 | $6M | -1633.7% | -1362.8% |
| FY2023 | $3M | -1704.7% | -1541.2% |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
How does DNTH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.